{"id":"4e43ce3091d9","type":"article","url":"https://hartvaat.nl/2026/02/01/implementatie-intelligentie-met-ai-prospectieve-evaluaties-nodig/","title":"Implementatie-intelligentie met AI: prospectieve evaluaties nodig","title_en":"Implementation Intelligence With AI—Prospective Evaluations Needed","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2841170","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2841170","authors":[],"significance":5,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":[],"congress":"","summary_en":"This editorial discusses the role of AI in improving detection of amyloid transthyretin cardiomyopathy and emphasises the critical need for prospective evaluations before clinical implementation of AI-based screening tools.","created":"2026-07-03T10:25:28Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De eerste fase 3-trial in 2018 met een transthyretinestabilisator voor ATTR-cardiomyopathie wakkerde interesse in betere detectie aan. Dit commentaar bespreekt de rol van AI bij implementatie en de noodzaak van prospectieve evaluaties.","abstract_original":"The publication of the first phase 3 randomized clinical trial in 2018 demonstrating benefit of a transthyretin stabilizer for the treatment of amyloid transthyretin cardiomyopathy (ATTR-CM) fueled a growing interest in improving detection of ATTR-CM. Concurrently, the emergence of artificial intelligence (AI)–based diagnostics has led to the development of a range of AI-based screening models, which leverage various combinations of structured data and unstructured data, such as electrocardiogram (ECG) waveforms and echocardiography images. These models have shown the potential to facilitate diagnosis of ATTR-CM, and the US Food and Drug Administration has cleared several AI-echo models for cardiac amyloidosis detection as Software as a Medical Device. However, prospective evaluation and clinical experience with these models remains limited and is critically needed prior to broad deployment."}